A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The Primary objective of this study is:
1. To determine the cardiac safety of TH-302 in patients with advanced solid tumors
The Secondary objectives are:
1. To assess the pharmacokinetics (PK) of TH-302
2. To evaluate whether there is an association between plasma exposure to TH-302 and its
active metabolite, Br-IPM, and effects on cardiac repolarization
3. To assess the safety and antitumor activity of TH-302 in patients with advanced solid
tumors